Combination inhibition of triple-negative breast cancer cell growth with CD36 siRNA-loaded DNA nanoprism and genistein. (9th July 2021)

• Record Type: Journal Article
• Authors: Wang, Beinuo; Yan, Ni; Wu, Di; Dou, Yin; Liu, Zhenyu; Hu, Xiaojuan; Chen, Cancan
• Is Part Of: Nanotechnology. Volume 32:Number 39(2021)
• Publication Date: 2021-07-09
• Subjects: CD36 siRNA -- DNA nanostructures -- genistein -- combination therapy -- MDA-MB-231 -- phospho-p38 MAPK -- triple-negative breast cancer cells; Nanotechnology -- Periodicals; Nanotechnology -- Periodicals; Nanotechnology; Publications périodiques; Nanotechnologies; Periodicals; 620.5
• DOI: 10.1088/1361-6528/ac0d1e
• Languages: English
• ISSNs: 0957-4484

Abstract

Abstract: Currently, a single treatment is less effective for triple-negative breast cancer (TNBC) therapy. Additionally, there are some limitations to the use of siRNA alone as a new method to treat breast cancer, such as its effective delivery into cells. In this study, we proposed a strategy that combines a siRNA-loaded DNA nanostructure and genistein for TNBC therapy. Both CD36 siRNA-loaded self-assembled DNA nanoprisms (NP-siCD36) and genistein knocked down CD36, resulting in enhanced anticancer efficacy through phosphorylation of the p38 MAPK pathway. In vitro studies showed that combination therapy could effectively enhance cell apoptosis and reduce cell proliferation, achieving an antitumor effect in TNBC cells. The current study suggests that NP-siCD36 combined with genistein might be a promising strategy for breast cancer and treatment.